Skip to main content
. 2022 Feb 19;23(4):2301. doi: 10.3390/ijms23042301

Figure 2.

Figure 2

Cell viability assays in MCF-7 (A) and NCI/ADR (B) with variable doses of free doxorubicin, SynB1 ELP DOXO, and SynB1 ELP GFLG-ncDox. Doses (nM) have been converted to logarithmic scale (X-axis).